Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer

A legfontosabb adatok

Ki végzi
VA Office of Research and Development
Hol
San Diego (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
6 fő vett részt
Kezdés
2023. nov. 20.
Befejezés
2025. márc. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • leucoselect phytosome
A regiszteradat frissítve
2026. február 17.
Miért állt le
Early termination by sponsor due to substantial delays with subjects recruitment

Ki vehet részt

Életkor
21 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Initial screening:
  • Lesions suspicious for lung cancer
  • Competent to provide consent
  • CBC within normal limits (WNL)
  • liver function test WNL
  • Normal Creatinine clearance as measured by the Cockcroft-Gault equation
  • ECOG Performance status: 0-1
  • Enrollment for treatment with LP:
  • Histologically proven and surgically resectable clinical I and II stage NSCLC

Ki nem vehet részt

  • Other concurrent malignancy, excluding non-melanoma type skin cancer
  • Have had a solid organ or bone marrow transplant
  • Systemic corticoid steroid therapy of > 10 mg prednisone equivalent daily
  • Concurrent use of Grapes or related products
  • Pts receiving medications known to be modulators of cytochrome P450 3A4 if alternative medication cannot be provided
  • Currently taking other investigational agents
  • Pts with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow up schedule
  • Inability to provide informed consent (e.g. cognitive impairment, severe psychiatric disorders)
  • Hypersensitivity to grapes or related products
  • Advance respiratory disease (Post resection FEV1 < 0.8 liters, resting hypoxemia, to ensure pts have adequate reserve to undergo diagnostic procedures and surgical resection)
  • Unstable angina
  • Coagulopathy (PT-INR > 1.2, PTT > 40 seconds) or history of bleeding/clotting problems
  • Pregnancy
  • Breast feeding
  • Unwilling to refrain from drinking more than 1 glass of wine a day

Helyszínek itt: Egyesült Államok

  • VA San Diego Healthcare System, San Diego, CASan Diego, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Lung cancer is the leading cause of cancer death in the country, surpassing deaths caused by colorectal, prostate and breast cancers combined. Veterans are at higher risk of lung cancer due to the higher rate of smoking and environmental toxin exposures. The lack of effective therapy for lung cancer provides the impetus to search for alternative, safe, and effective treatment agents to improve treatment strategy against lung cancer, enhance the probability of a cure and reduce recurrence. Based on encouraging preclinical and clinical findings from an early phase I lung cancer prevention study, using a special formulation of a standardized grape seed extract with enhanced absorption called leucoselect phytosome (LP), the purpose of this new CSR\&D Merit Review project is to evaluate the potential usefulness of LP for pre-surgical treatment of early stage lung cancer patients in a phase IIa clinical trial. Findings from this study may set the stage for larger, confirmatory trials in the near future.

A vizsgálat csoportja

  • InterventionA vizsgált kezelés

    All qualified participants meeting entry criteria that are enrolled will receive 2-3 weeks of oral LP treatment.

    Kezelés: leucoselect phytosome

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. február 17.